Dr Alan Taylor: How to Raise Capital and the Mission to Improve Cancer Treatment

March 16, 2022

Our host, Richard Sokolov, Executive Director and co-founder of IDE Group, speaks with Dr Alan Taylor, Executive Chairman of Clarity Pharmaceuticals.

Richard and Alan discuss advice on capital raising, the importance of having skin in the game, why intellectual property is so important in life sciences, how Clarity went from two provisional patents to the biggest IPO on the ASX, and many more topics.

About Dr Alan Taylor and Clarity Pharmaceuticals Alan is an expert on capital raising with 15 years of investment banking experience. Before joining Clarity, he was an Executive Director and shareholder of Inteq Limited, a boutique Australian investment bank. Alan has significant experience in capital raisings and mergers&acquisitions and has been involved in approximately $2 billion worth of transactions.

He joined Clarity when there was only a single founder and two provisional patents in 2013 and has recently led the Company through the largest ever biotechnology IPO on the Australian Securities Exchange, raising $92 million at a capitalisation of $358 million. Since joining Clarity, Alan has led over $140 million of capital raisings for the company.

Clarity is focused on theranostics, a field that combines therapy and diagnostics. It is developing Targeted Copper Theranostic (TCT) products, which allow copper isotopes to be used in the diagnosis and treatment of a range of cancers, including prostate and breast cancers, as well as rare and orphan cancer indications such as neuroblastoma - a childhood cancer that begins most often in the nerve cells outside of brain of infants and children younger than 5 years old.